Pfizer dofetilide reduces CHF hospitalization by 25% in DIAMOND study; mortality effect "neutral".
PFIZER DOFETILIDE DIAMOND STUDY SHOWS 25% REDUCTION IN CHF HOSPITALIZATION and no difference from placebo in the primary endpoint of all-cause mortality, study investigator Mogens Moller, MD, Odense University Hospital (Denmark), reported Aug. 26 at the European Society of Cardiology in Stockholm. Pfizer expects to file an NDA for the class III anti-arrhythmic drug in early 1998. Xelide has been mentioned as a potential brand name for dofetilide.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth